Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 14, 2007; 13(30): 4085-4090
Published online Aug 14, 2007. doi: 10.3748/wjg.v13.i30.4085
Published online Aug 14, 2007. doi: 10.3748/wjg.v13.i30.4085
Table 2 Response to lamivudine before breakthrough (mean ± SD)
HBeAg-positive hepatitis (n = 34) | HbeAg-negative hepatitis (n = 45) | |||||
All patients(n = 34) | BT(n = 14) | No BT(n = 20) | All patients(n = 45) | BT(n = 10) | No BT(n = 35) | |
Max suppression (log10 copies/mL) | 4.7 ± 1.4 | 4.8 ± 1.7 | 4.6 ± 1.2 | 4.3 ± 1.6 | 4.3 ± 1.7 | 4.3 ± 1.6 |
Initial suppression (log10 copies/mL) | 4.2 ± 1.7 | 4.2 ± 2.0 | 4.3 ± 1.5 | 3.3 ± 2.1 | 2.8 ± 2.5 | 3.4 ± 1.9 |
Patients with IVR (%) | 80 | 75 | 83 | 81 | 67 | 85 |
Patients at 6 mo biochemical response (%) | 90 | 82 | 94 | 84 | 86 | 83 |
Patients at 12 mo biochemical response (%) | 96 | 100 | 93 | 82 | 80 | 82 |
Time to first detection of BT | - | 26 ± 10 | - | - | 32 ± 12 | - |
- Citation: Chae HB, Hann HW. Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J Gastroenterol 2007; 13(30): 4085-4090
- URL: https://www.wjgnet.com/1007-9327/full/v13/i30/4085.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i30.4085